Introduction: β-HCG has been the only tumor marker evaluated in testicular vein (VT) blood until now. Objective: To evaluate the correlation between the tumor markers β-HCG, AFP, PLAP, and LDH from the VT and peripheral blood as well as their significance in predicting tumor recurrence and tumor stage. Methods: Patients with testicular cancer undergoing orchiectomy were studied retrospectively over a period of 20 years. Tumor stage, tumor histology, time to tumor recurrence, and tumor markers from VT and peripheral blood were analyzed. Minimal follow-up was 2 years. Statistical analysis was performed by means of Cox- and logistic regression models and Spearman rank correlation coefficients. Results: A total of 172 patients with an average follow-up of 9.9 years were investigated. The overall recurrence rate was 18% (seminoma patients 20.8%, nonseminoma patients 14.5%). Marker values measured from VT blood were higher than in peripheral blood and correlated strongly with the peripherally measured values. AFP obtained from peripheral blood was the only tumor marker allowing a statement on the recurrence probability. Tumor markers from VT blood showed no correlation with tumor stage. Discussion/Conclusion: Tumor markers from VT blood are significantly higher than in peripheral blood. Tumor markers obtained from VT blood do not provide clinical advantage in terms of assessing tumor stage and recurrence probability.

Keywords:
Tumor marker, Testicular vein, Testicular cancer
1.
Trigo
 
JM
,
Tabernero
 
JM
,
Paz-Ares
 
L
,
García-Llano
 
JL
,
Mora
 
J
,
Lianes
 
P
, et al. 
Tumor markers at the time of recurrence in patients with germ cell tumors
.
Cancer
.
2000
;
88
(
1
):
162
–
8
.
https://doi.org/10.1002/(sici)1097-0142(20000101)88:1%3c162::aid-cncr22%3e3.0.co;2-v
.
Google Scholar
PubMed
 
2.
Light
 
PA
,
Tyrrell
 
CJ
.
Testicular tumour markers in spermatic vein blood
.
Br J Urol
.
1987
;
59
(
1
):
74
–
5
.
https://doi.org/10.1111/j.1464-410x.1987.tb04584.x
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Mumperow
 
E
,
Kressel
 
K
,
Hartmann
 
M
.
Beta-HCG positive seminoma: incidence with special reference to tumor marker concentration in testicular venous blood
.
Urologe A
.
1991
;
30
(
2
):
114
–
6
.
Google Scholar
PubMed
 
4.
Zenico
 
T
,
Zoli
 
M
,
Fiori
 
M
,
Fabbri
 
F
,
Tamburini
 
C
,
Maltoni
 
G
.
Beta-human chorionic gonadotropin and alpha-fetoprotein in central and peripheral venous blood of patients with testicular tumors
.
Eur Urol
.
1992
;
21
(
Suppl 1
):
37
–
8
.
https://doi.org/10.1159/000474886
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Mumperow
 
E
,
Hartmann
 
M
.
Spermatic cord beta-human chorionic gonadotropin levels in seminoma and their clinical implications
.
J Urol
.
1992
;
147
(
4
):
1041
–
3
.
https://doi.org/10.1016/s0022-5347(17)37460-8
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Hartmann
 
M
,
Pottek
 
T
,
Bussar-Maatz
 
R
,
Weissbach
 
L
.
Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters
.
Eur Urol
.
1997
;
31
(
4
):
408
–
13
.
https://doi.org/10.1159/000474498
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Neumann
 
A
,
Keller
 
T
,
Jocham
 
D
,
Doehn
 
C
.
Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer
.
Aktuelle Urol
.
2011
;
42
:
311
–
5
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Hoshi
 
S
,
Suzuki
 
K
,
Ishidoya
 
S
,
Ohyama
 
C
,
Sato
 
M
,
Namima
 
T
, et al. 
Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients
.
Int J Urol
.
2000
;
7
(
6
):
218
–
23
.
https://doi.org/10.1046/j.1442-2042.2000.00181.x
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.